Effect of vaburbactam after retrograde intrarenal surgery

Studying the effect of oral vaburbactam on the incidence of systemic inflammatory response syndrome (SIRS) after retrograde intrarenal surgery (RIRS).

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190624043991N30

Enrollment

Registered

2025-03-12

Start date

2025-04-30

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney stones. Acute tubulo-interstitial nephritis

Interventions

Intervention 1: Intervention group: In the first group, 9% sodium chloride rinsing solution along with one gram of vaborbactam (Zagros Pharmed Pars Company) is added to one liter of rinsing solution o

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient treatment to participate in the study and obtain informed consent Age between 20 and 70 years Elective surgeries

Exclusion criteria

Exclusion criteria: History of renal colic History of stone excretion History TUL having anatomical or functional kidney disorders Use of NSAIDs, corticosteroids, or opioids Lack of patient satisfaction Immunodeficiency Use of immunodeficiency drugs History of thyroid problems

Design outcomes

Primary

Measure	Time frame
Changes in the incidence of SIRS caused by systemic inflammatory response syndrome (SIRS) due to the use of vaburbactam. Timepoint: 24 to 48 hours after the operation. Method of measurement: Medical diagnosis laboratory (Leukocytosis, CRP, ESR, positive urine culture).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Akram Mirzaei

Tehran University of Medical Sciences

mirzaee.scholar@gmail.com+98 21 6634 8560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026